PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

Chemotherapy 40

Chemotherapy Biosimilars Immunity Immunization 40

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines.

Immunity 52

Immunity Immunization Vaccines 52

European Pharmaceutical Review

DECEMBER 27, 2023

This is especially important due to the two unique toxicities of CAR T cells, namely CRS and the neurology toxicities that subsequently received the term immune effector cell- associated neurotoxicity syndrome (ICANS). This is in addition to its considerable price tag. Journal of Hematology & Oncology. Annals of Oncology.

Adverse Reactions 82

Adverse Reactions Immunity Immunization Medical Schools 82

PharmaShots

MARCH 9, 2023

Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. and Banco Bilbao Vizcaya Argentaria S.A LinkedIn Total experience: 16 yrs.

Clinical Pharmacology 40

Clinical Pharmacology Immunity Immunization Pharmaceutical Companies 40